Biotech company BunyaVax focuses on the rapid development of vaccines based on a promising new vaccine technology developed and patented by Wageningen Bioveterinary Research. This technology is based on virus particles that are capable of infecting cells only once, so called replicon particles.
The vaccine platforms are now used to generate vaccine candidates against several infectious diseases. BunyaVax is also exploring the application of the platforms for developing cancer immunotherapies. Proof of concept was already demonstrated for Rift Valley Fever, influenza and lymphoma.
The platform can be used to develop vaccines within weeks after the emergence of a (new) pathogen – which is highly valuable in case of an impending epidemic.